May 27, 2014 — RaySearch announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the extended version of its treatment planning system, RayStation 4.0.
The new version of RayStation 4.0 received CE mark in December 2013 and was released for clinical use in multiple markets. It contains tools for optimization of proton treatments using the pencil beam scanning (PBS) technique.
Proton therapy is considered the most advanced form of radiation therapy due to its superior dose distribution and fewer side effects. Protons deposit the majority of their energy within a precisely controlled range, thus making it easier to target the tumor and to spare healthy surrounding tissue. PBS is the most sophisticated technique to deliver proton therapy. It enables intensity-modulated proton therapy (IMPT) that allows clinicians to target a cancerous tumor by controlling both the intensity and the spatial distribution with millimeter precision. The proton module in RayStation contains all the state-of-the-art tools needed for PBS such as multiple field optimization, single-field uniform dose and distal edge tracking techniques.
“We have won several orders and been the most successful supplier of solutions for proton treatment planning over the last year. Our position on the U.S. market becomes even stronger now that we have market clearance for all relevant techniques for proton therapy,” said Johan Löf, CEO of RaySearch.
For more information: www.raysearchlabs.com